What is HER2-Low Breast Cancer?

HER2 Testing Breast Cancer: NEW Classifications (HER2 Low, Ultra Low) & Enhertu (Trastuzumab Deruxtecan) Explained! DESTINY-B04 & B06 Trial insights. Dr. Francisco J. Esteva, MD, PhD (Medical Oncology), explains the evolving landscape of HER2 testing in breast cancer and its profound impact on diagnosis, treatment strategies, and personalized care. Discover the new classifications like HER2 Low and HER2 Ultra Low, and understand how they are reshaping the future of breast cancer treatment. This video dives deep into the latest advancements, including critical findings from the groundbreaking DESTINY-Breast04 and DESTINY-Breast06 clinical trials. Learn about the revolutionary impact of trastuzumab deruxtecan (Enhertu) and what these significant changes in HER2 status and targeted therapies mean for patients with breast cancer, their caregivers, and oncology professionals. Stay informed on cutting-edge breast cancer research with insights on: • The evolution of HER2 testing and its significance. • Understanding HER2 Low and HER2 Ultra Low breast cancer classifications. • Key takeaways from the DESTINY-Breast04 (DESTINY-B04) trial. • Insights from the DESTINY-Breast06 (DESTINY-B06) trial. • The role of Trastuzumab Deruxtecan (Enhertu) in treating HER2-expressing breast cancers. • How these advancements lead to more personalized and effective treatment options. • Implications for HER2-positive, HER2-low, and HER2-negative breast cancer. #HER2 #BreastCancer #Enhertu #TrastuzumabDeruxtecan #HER2Low #DESTINYBreast04 #DESTINYBreast06 #CancerResearch #DrFranciscoEsteva #Oncology #PersonalizedMedicine #CancerTreatment Chapters 00:00 Introduction 00:18 HER2 biology 00:35 HER2 classsification 01:21 Trastuzumab Deruxtecan 01:32 DESTINY-B04 Trial 01:55 DESTINY-B06 Trial 03:19 Is HER2 Testing Necessary? 03:56 Antibody-Drug Conjugates in Development 04:09 Combination Therapy 04:37 Implications for Patient Management 05:34 Supportive Care 05:50 Future Research Directions 07:29 Conclusion About Dr. Esteva Francisco J. Esteva, MD, PhD is a medical oncologist based in New York with a specialization in breast cancer. He completed an Oncology Fellowship at Georgetown University Hospital and an Internal Medicine Residency at Cooper Medical School of Rowan University. Dr. Esteva serves as Division Chief at Lenox Hill Hospital and has previously held faculty appointments at NYU and The University of Texas MD Anderson Cancer Center. He has authored numerous peer-reviewed publications and has led more than 100 clinical trials focused on breast cancer treatment, diagnostics, and predictive biomarkers. His honors include Fellowship in the American College of Physicians, election to the American Society for Clinical Investigation, the 2019 Physician of Impact Award from Susan G. Komen NYC, and election to the NYC American Cancer Society Board of Advisors in 2024. Medical Disclaimer The content in this video is intended for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from your physician or another qualified health professional regarding any medical condition. Do not disregard professional medical advice or delay seeking care because of information presented in this video. The views shared in this video represent Dr. Esteva’s personal opinions and do not reflect those of his employer. Non-Sponsorship & Affiliation Disclaimer This video is not sponsored. Any mention of products, medications, or brands is for educational purposes only and does not imply endorsement. Advertisements that may appear are placed by YouTube; I am not affiliated with, nor do I endorse, any advertised products or services.